te

Bio-Techne

TECH
NASDAQ
$72.36

Bio-Techne a-t-elle une direction de haute qualité ?

Bio-Techne's management shows mixed results. Operational efficiency could be improved, and capital deployment decisions have been inconsistent. The team needs to demonstrate clearer focus on shareholder value creation.